|
Market Closed -
Other stock markets
|
After hours 12:52:18 | |||
| 245.80 EUR | -0.08% |
|
246.15 | +0.14% |
| 07-14 | Where would AI lead Pharma in the long run? | ![]() |
| 07-13 | Antengene Receives $60 Million Milestone in UCB Licensing Deal | MT |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| 26.36x | 3.98x | 1.91x | 5.45x | 16.03x | 19.87x | 0.6% | 53.32B | ||
| 17.35x | 1.96x | -1.96x | 3.71x | 9.57x | 11.1x | 0.59% | 66.74B | ||
| 37.26x | 7.61x | 0.7x | 12.6x | 24.05x | 28.31x | -.--% | 48.12B | ||
| -42.39x | 2.38x | 0.32x | 3.06x | 9.03x | 10.54x | 3.57% | 38.25B | ||
| 25.06x | 1.6x | -3.05x | 3.49x | 11.87x | 13.77x | -.--% | 29.85B | ||
| 56.96x | 4.21x | -0.84x | 3.39x | 25.31x | 27.38x | -.--% | 23.51B | ||
| -6.24x | 3.79x | -0.32x | 8.61x | -5.3x | -4.97x | -.--% | 21.45B | ||
| -37.77x | -6.7x | 0.92x | 18x | -49.29x | -56.96x | -.--% | 16.47B | ||
| 24.05x | 3.53x | 0.02x | 5.15x | 13.48x | 18.64x | -.--% | 16.38B | ||
| -116.91x | 12764.83x | 2.66x | 12.56x | -89.89x | -125.29x | -.--% | 12.4B | ||
| 17.57x | - | 0.2x | 3.61x | 13.96x | 16.3x | -.--% | 11.47B | ||
| 54.98x | 22.42x | 0.52x | 33.27x | 47.06x | 48.53x | 0.17% | 11.02B | ||
| 44.88x | - | 4.89x | - | - | - | -.--% | 9.88B | ||
| 12.81x | 1.14x | 0.46x | 1.85x | 7.44x | 10.05x | 2.69% | 6.62B | ||
| 59.53x | 4.21x | -0.77x | - | - | - | - | 5.65B | ||
| -44.6x | - | -0.8x | - | - | - | - | 5.62B | ||
| 27.25x | - | 1.34x | 7.29x | 19.35x | 23.11x | 0.38% | 5.56B | ||
| -108.39x | - | 7.18x | - | - | - | -.--% | 5.33B | ||
| 17.79x | 0.95x | 1.07x | - | - | - | - | 4.85B | ||
| 50.91x | 6.26x | 0.79x | 4.99x | 26.33x | 33.92x | -.--% | 4.83B | ||
| Average | 5.82x | 854.81x | 0.76x | 8.47x | 5.27x | 4.95x | 0.47% | 19.87B | |
| Weighted average by Cap. | 10.92x | 443.98x | 0.13x | 7.25x | 8.44x | 9.31x | 0.6% |
- Stock Market
- Stocks
- UCB Stock
- Sector UCB
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions

















